APIC-A2M is now ALPHA2ACTIVE™! We’ve redesigned our patented, 510(k) approved Alpha-2-Macroglobulin (A2M) therapy to reflect the worldwide expansion to come and give you an edge as you reopen in today’s medical climate. Read the official press release here. ALPHA2ACTIVE™ may have a fresh new look, but the single-use kits include the same easy processing steps, high A2M concentration and protease binding benefits as before.

ALPHA2ACTIVE™ is an exciting advancement in orthopedic science resulting from years of osteoarthritis research. For the majority of people with pain, their arthritic joint or disc space houses more destructive enzymes than the body can handle. Alpha-2-Macroglobulin, more commonly referred to as A2M, is a master protease inhibitor that already exists in your blood and acts as a powerful inhibitor of cartilage breakdown.

It is our body’s own defense mechanism.  This special molecule works by binding to the enzymes (proteases) that degrade the cartilage cells and tissue. However, it is too big and complex to enter the joint or disc space in large enough quantities. As a result, it is necessary to inject additional concentrated A2M into the affected area to restore balance and relieve pain.

A patented and proprietary filtration process has been developed that can concentrate the naturally occurring A2M molecule from a patient’s own blood up to 6X! This process allows therapeutic injections in concentrated dosages that:

• Boost natural healing by reducing the additional deterioration of cartilage and inflammation
• First and only system to centrifuge and filter plasma
• Settings for both PRP and PPP processing
• Low percentage of white blood cells eliminating unnecessary pain from the treatment
• Support tissue growth with naturally occurring compounds from your own blood